Skip to main content
Publications
Neal J, Lee JB, Ahn MJ, Ariyasu R, nash C, Smith D, Nagar S , Jimenez M , Kahangire DA, Kim YJ, Nasirova F, Lin S. Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): interim analysis of a global real-world (RW) study . Poster presented at the European Lung Cancer Congress (ELCC) 2024; March 20, 2024. Prague, Czech Republic.
McElwee N, Willke R, Barrette E, Berger M, Cole A, Cortesi P, Earnshaw S , Garrison L, Gonzalez-Pier E, IJzerman M, Lee V, Hanson J, Mauskopf J , Reed S. Towards a vision for HEOR: opportunities for enhancement and evolution - an ISPOR health science policy council white paper . 2024. Available at: https://www.ispor.org/member-groups/councils-roundtables/health-science-policy-council. Accessed April 5, 2024.
Dolin P, Kielar D, Shavit A, Koegh K, Rowell J, Edmonds C, Meyers J , Esterberg E , Nham T , Chen S. Comorbidities in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data . Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 23, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB53.
Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J , Esterberg L , Nham T , Chen S. Healthcare resource utilization and costs in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data . Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 25, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB206.
Niyazov A, Simou E , Kirker M, Houghton K , Le Moine JG , Chang J, Yarr S , Barnett C , Mladsi D . Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Niyazov A, Simou E , Kirker M, Houghton K , Le Moine JG , Chang J, Yarr S , Barnett C , Mladsi D . Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Spelman T, Herring WL , Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, Van Pesch V, Van Mijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Trivino T, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Izquierdo G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara C, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom . J Med Econ. 2023 Dec;27(1):109-25. doi: 10.1080/13696998.2023.2293379
Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N , Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Corrigendum to Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report: [Value in Health 25 (2022) 1257-1267/3488] . Value Health. 2023 Dec;26(12):1811. doi: 10.1016/j.jval.2023.06.010